Clinical Trial Update: Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study assessing topical PF-06700841 for efficacy, safety, tolerability, and PK in mild to moderate atopic dermatitis; study completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• PF-06700841 topical cream (PF-06700841)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-03-29